Antisense Therapeutics |
Market Cap (5-Nov) TBC |
Close (30-Jun) $0.059 |
Volume (30-Jun) 4,352,698 |
Shortsold (24-Jul) 256 (0.00%) (719th) |
|
52w High $0.000 |
52w Low $0.000 |
P/E - |
EPS - |
Proposed issue of securities - ANP
ANP released this announcement to the ASX on 6 March 2023, 16:32. The announcement is not marked as price sensitive, and is 5 page(s) in length and 24.49kb in size.
You can view all announcements from ANP and see how they appear on a price chart on the announcements page.
At the date of this announcement, ANP was 0.022% short sold according to ASIC data. It was ranked the 553rd most shorted stock on the ASX. It remains ranked 719th as of the latest reported data (24 July 2023).
| Other Recent Announcements from ANP | |
|---|---|
| MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK | 27 June 2023, 15:46 |
| First Patient Dosed in ATL1102 Phase IIb DMD Trial | 8 June 2023, 8:38 |
| Shareholder Newsletter | 6 June 2023, 15:47 |
| Proposed issue of securities - ANP | 6 March 2023, 16:32 |
| Receipt of R&D Tax Incentive Payment | 23 February 2023, 9:11 |
| Half Yearly Report and Accounts | 22 February 2023, 16:24 |
| Presentation at International Conference on DMD | 17 February 2023, 9:42 |
If you were already registered, log in here.